Trivant Custom Portfolio Group, LLC Travere Therapeutics, Inc. Transaction History
Trivant Custom Portfolio Group, LLC
- $174 Billion
- Q1 2025
A detailed history of Trivant Custom Portfolio Group, LLC transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Trivant Custom Portfolio Group, LLC holds 100 shares of TVTX stock, worth $1,468. This represents 0.0% of its overall portfolio holdings.
Number of Shares
100Holding current value
$1,468% of portfolio
0.0%Shares
2 transactions
Others Institutions Holding TVTX
# of Institutions
239Shares Held
99.9MCall Options Held
1.79MPut Options Held
555K-
Armistice Capital, LLC New York, NY8.87MShares$130 Million2.42% of portfolio
-
Black Rock Inc. New York, NY7.64MShares$112 Million0.0% of portfolio
-
Janus Henderson Group PLC London, X07.53MShares$111 Million0.08% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.01MShares$73.6 Million0.0% of portfolio
-
Macquarie Group LTD Australia, C34.8MShares$70.4 Million0.11% of portfolio
About Travere Therapeutics, Inc.
- Ticker TVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,173,600
- Market Cap $942M
- Description
- Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...